Huntington disease
Top Cited Papers
- 23 April 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Disease Primers
- Vol. 1 (1), 15005
- https://doi.org/10.1038/nrdp.2015.5
Abstract
Huntington disease is devastating to patients and their families — with autosomal dominant inheritance, onset typically in the prime of adult life, progressive course, and a combination of motor, cognitive and behavioural features. The disease is caused by an expanded CAG trinucleotide repeat (of variable length) in HTT, the gene that encodes the protein huntingtin. In mutation carriers, huntingtin is produced with abnormally long polyglutamine sequences that confer toxic gains of function and predispose the protein to fragmentation, resulting in neuronal dysfunction and death. In this Primer, we review the epidemiology of Huntington disease, noting that prevalence is higher than previously thought, geographically variable and increasing. We describe the relationship between CAG repeat length and clinical phenotype, as well as the concept of genetic modifiers of the disease. We discuss normal huntingtin protein function, evidence for differential toxicity of mutant huntingtin variants, theories of huntingtin aggregation and the many different mechanisms of Huntington disease pathogenesis. We describe the genetic and clinical diagnosis of the condition, its clinical assessment and the multidisciplinary management of symptoms, given the absence of effective disease-modifying therapies. We review past and present clinical trials and therapeutic strategies under investigation, including impending trials of targeted huntingtin-lowering drugs and the progress in development of biomarkers that will support the next generation of trials. For an illustrated summary of this Primer, visit: http://go.nature.com/hPMENhKeywords
This publication has 237 references indexed in Scilit:
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin SynthesisNeuron, 2012
- Health-related quality of life in Huntington’s disease patients: a comparison of proxy assessment and patient self-rating using the disease-specific Huntington’s disease health-related quality of life questionnaire (HDQoL)Zeitschrift für Neurologie, 2012
- Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Slow Amyloid Nucleation via α-Helix-Rich Oligomeric Intermediates in Short Polyglutamine-Containing Huntingtin FragmentsJournal of Molecular Biology, 2012
- Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates NeurodegenerationCell, 2011
- Cognitive and functional decline in Huntington's disease: Dementia criteria revisitedMovement Disorders, 2010
- A Two-Step Path to Inclusion Formation of Huntingtin Peptides Revealed by Number and Brightness AnalysisBiophysical Journal, 2010
- CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approachesAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2010
- CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing HaplogroupAmerican Journal of Human Genetics, 2009
- Living at Risk: Concealing Risk and Preserving Hope in Huntington DiseaseJournal of Genetic Counseling, 2007